Galegenimab (development codes FHTR2163 and RO7171009) is an investigational biologic agent engineered as a fragment antigen-binding (Fab) derived from a humanized monoclonal antibody. It is designed for potential therapeutic applications where modulation of a specific extracellular protease is desired. Its unique Fab format, lacking the Fc region of a full antibody, is chosen to facilitate specific tissue penetration, reduce potential effector functions, and achieve a distinct pharmacokinetic profile. Galegenimab functions by specifically binding to and inhibiting the enzymatic activity of its target protein, HtrA1 (High-temperature requirement A serine peptidase 1), thereby aiming to modulate the proteolytic processes in which HtrA1 is involved.